Physician profile
Barbara K Ariue
NPI 1013930874
$111,980.59
in general payments reported to CMS, 2019-2025
33 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,754 · 2020: $2,137 · 2021: $479 · 2022: $382 · 2023: $19K · 2024: $66K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Travel and Lodging: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Food and Beverage: $4,748 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,931.38 |
| Travel and Lodging | $11,696.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,599.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,000.00 |
| Food and Beverage | $4,748.37 |
| Education | $252.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $82,322.49 | 2021-2025 | Joenja, Ruconest |
| Glaxosmithkline, LLC. | $10,262.09 | 2022-2025 | Nucala |
| Csl Behring | $8,531.23 | 2021-2025 | Andembry |
| Optinose US, INC. | $3,474.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $2,321.95 | 2020-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $1,599.00 | 2024 | Dupixent |
| Genzyme Corporation | $684.25 | 2023-2025 | |
| Alk-Abello, INC | $642.12 | 2020-2025 | Grastek, Odactra, Ragwitek |
| Takeda Pharmaceuticals U.S.A., INC. | $425.68 | 2022-2025 | Takhzyro, Cinryze |
| Astrazeneca Pharmaceuticals Lp | $300.51 | 2022-2025 | Fasenra, Tezspire |
| Sanofi-Aventis U.S. LLC | $178.94 | 2023-2024 | |
| Circassia INC. | $175.60 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $157.44 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $139.82 | 2023-2025 | Orladeyo |
| Blueprint Medicines Corporation | $109.36 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75.00 | 2019 | |
| Ionis Pharmaceuticals, INC. | $72.02 | 2025 | Dawnzera |
| Philips North America LLC | $54.89 | 2023-2025 | Respiratory, Encore |
| Covis Pharma Gmbh | $51.59 | 2022 | |
| Cycle Pharmaceuticals INC | $51.04 | 2025 | Sajazir |
| Novartis Pharmaceuticals Corporation | $47.67 | 2023-2024 | |
| Amgen INC. | $44.24 | 2024-2025 | Tezspire |
| Kyowa Kirin, INC. | $41.51 | 2025 | |
| Merck Sharp & Dohme LLC | $30.09 | 2023 | |
| Genentech USA, INC. | $28.53 | 2019 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Pfizer INC. | $26.80 | 2024 | |
| Abbott Laboratories | $22.84 | 2023 | 2nd Gen Centrimag Primary Console |
| Hikma Pharmaceuticals USA | $19.98 | 2024 | Ryaltris |
| Sobi, INC | $19.95 | 2023 | |
| Galderma Laboratories, L.P. | $18.63 | 2025 | Nemluvio |
| Phadia US INC. | $16.04 | 2023 | Immunocap |
| Adma Biomanufacturing LLC | $7.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Ariue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.